CN Patent
CN102666546B — N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式
Assigned to Vertex Pharmaceuticals Inc · Expires 2015-09-09 · 11y expired
What this patent protects
本发明涉及N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺(形式A-HCl、形式B、形式B-HCl或这些形式的任意组合)的基本上晶体和固态形式,其药物组合物,及采用其的治疗方法。
USPTO Abstract
本发明涉及N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺(形式A-HCl、形式B、形式B-HCl或这些形式的任意组合)的基本上晶体和固态形式,其药物组合物,及采用其的治疗方法。
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.